By PPN News Staff
The FDA approved lanadelumab-flyo (Takhzyro, Shire), the first monoclonal antibody (mAb) approved in the United States to prevent attacks of hereditary angioedema (HAE) in patients aged 12 years and older.
HAE is a rare and serious genetic disease that affects people with low levels of and poorly functioning C1 esterase inhibitor proteins in the body, which results in recurrent, unpredictable episodes of edema in different areas of the body, including the stomach, limbs,